Remarkably, doxycycline inhibited growth of all tested DLBCL cells, including cells that are resistant to several currently-tested inhibitors that target HSP90 or the upstream regulators of the BCR signaling pathway in B-cell lymphomas [53, 76]. This evidence concerns the gene BCR and B-cell non-Hodgkin lymphoma.